The University of Southampton
University of Southampton Institutional Repository

Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization

Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization
Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization
Aminoimidazole carboxamide ribonucleotide transformylase/ inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis. Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å(2) , is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins. Here, we report the development of a small-molecule inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC. The compound is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a K(i) of 17 ?M), identified by high-throughput screening. The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analogue of which inhibits AICAR transformylase with a K(i) value of 84 ?M. A library of nonnatural analogues of this dipeptide was designed, synthesized, and assayed. The most potent compound inhibits AICAR transformylase with a K(i) value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide. The potential for this AICAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line. Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent reduction in cell numbers and cell division rates was observed in cells treated with our ATIC dimerization inhibitor.
AICAR transformylase, ATIC, cancer, peptides, protein–protein interaction inhibitors
1439-4227
1628-1634
Spurr, Ian B.
fb87bcbc-46d2-4cb0-8240-ecdfaf013d1d
Birts, Charles N.
8689ddad-ba47-4ca6-82c5-001315dbd250
Cuda, Francesco
8c738a55-70a8-4063-b063-bf83cdf0f270
Benkovic, Stephen J.
f85498a5-27fc-4a22-9069-ff61a4297520
Blaydes, Jeremy P.
e957f999-fd91-4f77-ad62-5b4ef069b15b
Tavassoli, Ali
d561cf8f-2669-46b5-b6e1-2016c85d63b2
Spurr, Ian B.
fb87bcbc-46d2-4cb0-8240-ecdfaf013d1d
Birts, Charles N.
8689ddad-ba47-4ca6-82c5-001315dbd250
Cuda, Francesco
8c738a55-70a8-4063-b063-bf83cdf0f270
Benkovic, Stephen J.
f85498a5-27fc-4a22-9069-ff61a4297520
Blaydes, Jeremy P.
e957f999-fd91-4f77-ad62-5b4ef069b15b
Tavassoli, Ali
d561cf8f-2669-46b5-b6e1-2016c85d63b2

Spurr, Ian B., Birts, Charles N., Cuda, Francesco, Benkovic, Stephen J., Blaydes, Jeremy P. and Tavassoli, Ali (2012) Targeting tumour proliferation with a small-molecule inhibitor of AICAR Transformylase Homodimerization. ChemBioChem, 13 (11), 1628-1634. (doi:10.1002/cbic.201200279). (PMID:22764122)

Record type: Article

Abstract

Aminoimidazole carboxamide ribonucleotide transformylase/ inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis. Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å(2) , is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins. Here, we report the development of a small-molecule inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC. The compound is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a K(i) of 17 ?M), identified by high-throughput screening. The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analogue of which inhibits AICAR transformylase with a K(i) value of 84 ?M. A library of nonnatural analogues of this dipeptide was designed, synthesized, and assayed. The most potent compound inhibits AICAR transformylase with a K(i) value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide. The potential for this AICAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line. Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent reduction in cell numbers and cell division rates was observed in cells treated with our ATIC dimerization inhibitor.

Full text not available from this repository.

More information

Published date: 4 July 2012
Keywords: AICAR transformylase, ATIC, cancer, peptides, protein–protein interaction inhibitors
Organisations: Chemistry, Cancer Sciences, Organic Chemistry: SCF

Identifiers

Local EPrints ID: 341205
URI: https://eprints.soton.ac.uk/id/eprint/341205
ISSN: 1439-4227
PURE UUID: 6abcfb52-4705-44bf-bc4e-034268e6c31f
ORCID for Charles N. Birts: ORCID iD orcid.org/0000-0002-0368-8766
ORCID for Jeremy P. Blaydes: ORCID iD orcid.org/0000-0001-8525-0209
ORCID for Ali Tavassoli: ORCID iD orcid.org/0000-0002-7420-5063

Catalogue record

Date deposited: 23 Jul 2012 10:59
Last modified: 18 May 2019 00:36

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×